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Conclusions: VinV –TAVI is widely performed, albeit in small numbers, in majority of
centers in the Nordic countries. The short-term results are excellent on this high-risk
patient population, demonstrating a low incidence of procedure-related complications.
However, a number of patients are left with suboptimal systolic valve performance with
unknown long-term effects, warranting a close surveillance after VinV-TAVI.
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Background: The last few years, transcatheter aortic valve implantation (TAVI) has
evolved as a good alternative treatment for patients rejected or with high risk for aortic
valve replacement (AVR). Very few studies report reasons for rejection for TAVI and the
outcome of these rejected patients. The purpose of this study is to investigate the reasons
for rejection for TAVI and compare survival between rejected and treated patients.
Methods: In this retrospective single center study patients referred for TAVI between
October 2007 and September 2011 are included. Reasons for rejection for TAVI were
collected and survival was compared for conservative treatment with transfemoral or
transapical TAVI and surgical AVR.
Results: We included 374 patients(mean age 81 years, 49% male); 150 patients were
rejected for TAVI. Reasons for rejection were: multiple comorbidities (24%), surgical
candidate (14%), other heart disorders (poor left ventricular function and/or other valve
abnormalities) (10%), asymptomatic or no severe aortic stenosis (7%), poor renal
function, malignancy, severely impaired lung function, cognitive reasons, poor peripheral
vessels and extreme high age. A total of 160 patients were treated by transfemoral TAVI
and 64 patients by transapical TAVI. Patients treated by TAVI or surgically had a
significant better 2-year survival than patients treated conservatively.
Conclusions: There are many reasons for rejection for TAVI, but the main reason was
multiple comorbidities. Patients with symptomatic severe aortic valve stenosis treated by
TAVI or surgical have a better survival than patients treated conservative.
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Background: Severe aortic regurgitation (AR), when intervention is required, is
managed by surgical aortic valve replacement (SAVR). TAVR could be a valid “off label”
option to treat severe AR for patients unsuitable for SAVR due to their high surgical risk.
However, in severe AR, large aortic annulus and poor aortic valve calcifications made
challenging TAVR. We hereby report our single centre experience of 8 cases (see Table)
of AR in which surgical correction was excluded because of high predicted operative
mortality. These cases were treated with TAVR using Medtronic CoreValve prostesis.
Total of patients 8
Age y (mean) 81
NYHA class III-IV pre TAVR % I00
L-Euroscore % 31
2 valve requirement (valve-in-valve) 0%
Ao regurgitation post TAVR  2 20%
New permanent PM implantation % 40
6 month mortality none
Methods: In all cases an oversizing prosthesis was used. Pre-dilation with balloon
valvuloplasty was never performed. During valve deployment a rapid (180 bpm) pacing
was used in order to prevent valve ejection.
Results: In our patients there were no peri-procedural major complications (stroke, major
bleeding). A new permanent PM implantation was necessary in 3 pts. At the 30-days and
6-month follow up we observed an improved functional capacity and no death.
Conclusions: TAVR in AR remains an off-label application needing further study.
However in selected cases may be considered as a valid option to treat severe AR in
patients unsuitable for SAVR.
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Background: TAVR has become a standard therapy for patients with severe aortic
stenosis considered to be inoperable or at very high risk for surgery. For both types of
currently available prostheses (the selfexpanding CoreValve (Medtronic, Minneapolis,
MN) and the ballon-expandable Edwards–Sapien XT (Edwards Lifesciences, Irvine, CA))
the standard procedure includes a balloon predilation as part of the procedure before
implanting the actual device. Although predilation of the calcified valve may facilitate
device placement, it bears a risk of stroke and conduction disturbances, two major
drawbacks of this procedure.
Methods: We performed a prospective study in 74 consecutive patients to investigate the
feasibility and procedural results of direct implantation of the selfexpanding Medtronic
CoreValve prosthesis without predilation.
Results: A total of 74 consecutive patients implanted with a CoreValve aortic biopros-
thesis were included in our study. Successful implantation was achieved in 73 (98.6%) of
the patients. Postdilation was necessary in 27% of the cases. Evaluation of outcome after
30 days showed a stroke/TIA rate of 2.7% with a 1.3% rate of major stroke. At 30 days
need for permanent pacemaker insertion post TAVR was 21.7% and overall mortality was
4.1 %. Procedural results showed an average implantation depth of 5.93.2 mm below
the annulus line and a rate of postprocedural aortic regurgitation  grade 2 of 1.4%.
Conclusions: Direct implantation of the CoreValve selfexpanding aortic bioprosthesis
without predilation is feasible and may be a safe alternative to the standard procedure
using predilation. Procedural results showed a low number of strokes and need for
postinterventional pacemaker implantation. Prospective studies should be performed to
compare both techniques of implantation with respect to periprocedural stroke rates and
need for pacemaker implantation.
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Background: Elevated concentrations of troponin T (cTnT) have prognostic impact in
patients with aortic stenosis. For patients with high risk for conventional aortic valve
replacement, transcatheter aortic valve replacement (TAVR) has become an established
therapeutic option.
Methods: We conducted a retrospective analysis in 201 consecutive patients scheduled
for transfemoral TAVR and analyzed predictors, kinetics and prognostic values of pre-
and postinterventional troponin T levels by using a high sensitive troponin T assay (Roche
Diagnostics).
Results: Patients with severe aortic stenosis had significantly elevated levels of cTnT
detectable before TAVR. Postinterventional cTnT levels rose significantly about seven
fold after transfemoral TAVR. Cardiac cTnT levels were highest at day 3 after TAVR
(204 11 pg/ml (mean SEM) compared to 43 3.1 pg/ml before TAVR) and steadily
declined thereafter. Baseline renal function (p0.011), the duration of intraprocedural
rapid pacing (P0.0012) left ventricular mass (p0.01) and baseline cTnT (p0.0001)
values were related to postinterventional cTnT release. Interestingly, Kaplan-Meier
survival curve analysis revealed, that although cTnT levels were not predictive for
shortterm mortality, preinterventional as well as postinterventional peak cTnT showed
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